
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical ointment containing diphenylcyclopropenone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No finished diphencyprone (diphenylcyclopropenone) product of any kind is listed; the directory holds only a bulk ingredient record for it.
Bases for this dose form are usually nonaqueous. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Diphenylcyclopropenone (DPCP, diphencyprone) is a topical contact sensitizer used in skin immunotherapy; compounded preparations require a prescription and are not FDA-approved.
Diphenylcyclopropenone, also called diphencyprone or DPCP, is a chemical that sensitizes the skin and triggers an allergic contact reaction where it is applied. No FDA-approved drug product contains it: Drugs@FDA lists no application, DailyMed has no product label, and the FDA NDC directory lists only a bulk powder marketed for human prescription compounding. FDA regulations include diphenylcyclopropenone, for topical use only, on the list of bulk drug substances that can be used in compounding under section 503A. Its use for alopecia areata was reported by Happle and colleagues in 1983, and DermNet notes that some dermatology centers use it and that it may be useful for hard to treat warts. One idea is that the induced skin reaction draws immune activity away from hair follicles, but how it acts has not been established. Compounded preparations are not FDA-approved and require a prescription.
Because there is no FDA-approved product, there is no FDA label with boxed warnings or interaction lists. DPCP is meant to cause a skin reaction, so mild redness and itching are expected. A 2021 review lists dermatitis and hives among its side effects, along with swelling (angioedema), severe allergic reactions, fever and erythema multiforme-like reactions. Severe reactions can include burning, blistering and swelling, swollen lymph nodes behind the ears, and lasting pigment changes, including loss of skin color (vitiligo). Gloves should be worn for each application, because a partner or health care worker can also become sensitized. Treated skin should be covered for the first 24 hours, since sunlight breaks DPCP down. DermNet advises against use in pregnancy or when planning pregnancy because safety data are lacking. No lactation data source was found. For side effects, talk to your prescriber or pharmacist.
DPCP is a contact sensitizer for topical immunotherapy. Proposed mechanisms in alopecia areata include antigenic competition, in which induced allergic contact dermatitis redirects T cell activity away from the hair follicle, and a shift in cytokines toward a regulatory profile; a 2021 review states both need further evidence. The protocol described in a 2021 review is an initial sensitization application followed by weekly applications at a low starting strength titrated to the skin reaction; strengths per prescriber. DPCP is reported as nonmutagenic in the Ames assay with no reported systemic absorption, though DermNet notes its precursor and possible manufacturing contaminant, alpha,alpha'-dibromodibenzyl ketone, can be mutagenic. DermNet advises storing it in a dark glass bottle away from sunlight, and a 2021 review describes amber glass storage away from sunlight for topical sensitizers. Patients with high serum IgE may have more severe reactions. A 2021 review describes DPCP immunotherapy for alopecia areata, and a 2013 retrospective study describes its use for periungual warts. These are not FDA-approved indications; no FDA-approved product exists. Strength is adjusted according to the local skin reaction, and DermNet describes potent topical steroids, cool compresses or a short oral steroid course for severe reactions. 21 CFR 216.23 limits 503A compounding with this bulk substance to topical use.
Wash your hands. Apply a thin layer to the affected area and rub in gently as your label directs. Do not cover with a bandage or wrap unless your prescriber tells you to. Keep it out of your eyes. Do not apply to open wounds or broken skin unless told to. Wash your hands after applying.
Ointments are usually nonaqueous, so a USP <795> default beyond-use date of up to 180 days may apply when no other data exist. Store in the closed container at room temperature, away from heat and direct light, keep from freezing, and keep out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)